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INTRODUCTION
Osteoarthritis (OA) is a progressive chronic disease potentially affecting every articular 
tissue and may potentially lead to joint failure. It has heterogeneous manifestation and, does 
not always have the same appearance in all patients. Indeed, OA may present differently in 
men and women, in patients with or without trauma, in athletes, or in obese patients [1,2]. OA 
articular cartilage changes result from the disruption of the normal balance between anabolic 
and catabolic processes, as well as cellular abnormalities in autocrine, paracrine, and endo-
crine regulation, leading to a disequilibrium in normal tissue turnover within the joint [2].
Numerous factors have been associated with an increased risk for the development of OA. 
These include systemic factors such as genetics, age and gender, sex hormones, bone mineral 
density, as well as local mechanical factors such as joint overload caused by obesity, acute 
injury, repetitive joint loading, and joint deformity [3]. Despite the multifactorial nature of 
OA, the pathological changes seen in osteoarthritic joints have common features that affect 
the entire joint structure resulting in pain, deformity, and loss of function [4].
OA can be defined in terms of radiologic changes as well as symptoms, although there 
may be a discordance between these findings since many people with pathologic and radio-
graphic evidence of osteoarthritis have no symptoms [5]. From a clinical perspective, pain 
is the disease characteristic that negatively affects multiple aspects of patient’s life, includ-
ing mobility, sleep, mood, and health related quality of life (HRQoL) [6]. Pain and function 
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are core symptomatic outcomes of OA that are frequently targeted as part of pharmacologic 
therapy, and it may be expected that these outcomes are associated with patient perceptions 
of OA severity [7].
A variety of pharmacologic options are available for managing OA-related pain such as 
simple analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), oral corticosteroids, opi-
oids, and injectables including corticosteroids and viscosupplementation with hyaluronan [8]. 
As occurs with most chronic conditions, adherence to OA medications is low. Factors impli-
cated in adherence to OA include dosing frequency, self-efficacy levels, and physician and 
patient treatment satisfaction [9].
While simple analgesics and NSAIDs are generally recommended as first-line pharmaco-
logic therapy, in clinical practice choosing among these medications is often determined by 
disease severity [10]. In clinical trials, definitions of severity are generally based on cut-points 
for patient-reported pain, function, and global assessments. However, in real-world settings, 
categorizing mild, moderate, or severe disease based solely on pain cut-points may be neither 
comprehensive nor relevant from the patient’s perspective. Other factors such as functional 
impairment and work productivity may also contribute to a patient’s overall perception of dis-
ease severity [11,12]. As a result, patients with OA report impairment of their ability to carry 
out activities of daily living in addition to deterioration in HRQoL.
As a consequence, OA patients are very high users of health care services and incur higher 
costs than patients without OA, due to the duration of disease and the level of impairment 
related to their illness [13]. The burden of OA is therefore considerable, both from a societal 
and individual patient perspective [14]. OA is responsible for a very high number of primary 
healthcare visits as well as knee and hip replacement procedures, plus hospital admission 
costs, as well as assistance for follow-up and rehabilitation [15]. However, the socio-eco-
nomic burden of OA is not only limited to the direct costs of healthcare use, but also includes 
significant non-healthcare-related costs. These take the form of productivity losses and the 
cost of formal and informal care associated with the limited independence of people with 
osteoarthritis [15].
Considering Disability Adjusted Life Years (DALYs) over the period 1990-2010, OA bur-
den of disease has grown at a faster pace than musculoskeletal diseases (64% vs 45%) [16]. 
According to the Italian Health Ministry, OA resulted to be the 7th out of 283 diagnosis for 
Clinical Classifications Software (CCS) for number of hospital discharges from hospital data 
collected in 2014 [16]. Hospital discharges for OA in Italy were 127,000, close to the 2% of 
the discharges with an average hospital stay of 7.5 days [17]. In Italy annual total costs per 
patient have been estimated €3,000 (€1,300 as direct health-related costs and €1,700 as in-
direct costs adjusted in 2013) [18]. Recently, Berto and Aiello conducted a literature review, 
revealing that the impact of OA on the Health System, generates direct health costs related to 
hospital admissions for hip and knee surgery; and may generate additional costs due to relaps-
es, need for intervention review, adverse events (e.g., infections, thrombosis and pulmonary 
embolisms) and subsequently to the rehabilitation process, in hospital and at home. They also 
reported the burden of illness also generated by indirect costs characterized by the reduced or 
lack of productivity of patient and family members, as patients with OA are affected by severe 
limitations in daily and work activities [19].
Overall, OA is a chronic condition that impacts significantly on life expectancy and pa-
tients’ HRQoL and generates considerable costs to most health care systems. As with any 
chronic condition, non-adherence to the available pharmacological treatments is a problem 
that has the potential to impact on population health and expenditure.
Given that OA exerts multiple effects on patients’ lives, the objective of this study was to 
determine how patient-rated OA severity (mild, moderate and severe) can affect self-reported 
outcomes relevant from the patient’s perspective, including assistance with mobility and daily 
activities. Additionally, this study aims to understand the pattern of healthcare resource utili-
zation (HCRU) in Italy as OA severity worsens.
METHODS
Study Design
This study utilized data from the 2017-18 Osteoarthritis Adelphi Disease Specific Pro-
gramme (DSP)TM. The Adelphi DSP is a large, multinational, point in time survey designed to 
capture a cross-section of real-world data for a range of common chronic diseases [20]. Data 
were collected in Italian clinical practice settings from primary care physicians, rheumatolo-
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gists, orthopedists, and their patients with OA, during their regular office visits. Physicians 
completed patient record forms (PRFs) on their next 9 consecutive patients ≥18 years) con-
sulting for OA, plus an oversample of 1 patient who had tried at least 3 prescribed medica-
tions for their OA pain. These patients were also invited to participate by providing written 
informed consent and completing a patient self-completion questionnaire (PSC). Physicians 
completed information about OA-related visits to healthcare professionals (HCPs), tests/scans 
conducted, emergency room (ER) visits, surgeries, and OA-related treatment. Physicians also 
rated patients’ functioning on a 0 to 10 scale (0 = fully functional; 10 = completely impaired).
OA pain intensity and physical function were measured using the Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC), a widely used, validated, self-ad-
ministered, disease-specific questionnaire [21]. Patients rated their average pain intensity over 
the last week on a 0-10 scale (0 = no pain; 10 = worst possible pain) and, using the pain com-
ponent of the WOMAC, were categorized into mild (0-3), moderate (4-6) and severe (7-10) 
pain groups.
Patients also provided an assessment of their physical function (0-10 WOMAC scale 
where higher scores indicated greater functional impairment), impact on mobility, whether 
caregiver assistance was required, and daily activities requiring caregiver assistance.
The analysis was conducted using combined data from the total patient sample (random 
sample + over-sample). Not all physicians and patients answered all the questions on the PRF 
and PSC, respectively. Consequently, the respondent population size may differ for individual 
questions and thus for certain analyses. The population size is given for each individual analy-
sis where appropriate and indicates the number of respondents (physician or patient) who 
provided responses relevant to that analysis.
Outcome Measures
Outcomes included measures for physical functioning, HRQoL, pain, work productivity 
and daily activity. Physical functioning was reported by patients using pain, physical function 
and stiffness scores from the WOMAC which are scored on a range from 0 to 10. Generic 
HRQoL was assessed using the EuroQoL-5 Dimension (EQ-5D) instrument [22]. The EQ-5D 
includes a separate visual analogue scale (VAS) which varies from 0 = worst health you can 
imagine to 100 = best health you can imagine [22]. Work productivity and daily activity were 
assessed using the patient-reported Work Productivity and Activity Impairment Questionnaire 
(WPAI). WPAI scores are based on 1-item (presenteeism, activity impairment), 2-items (ab-
senteeism) and multiple items (overall work productivity).
Statistical Analysis
Descriptive statistics (numbers and percent for categorical variables; means with standard 
deviations [SD] for continuous variables) were used to evaluate the different variables as ap-
propriate.
RESULTS
Demographic and Clinical Characteristics
A total of 90 physicians were included in the analysis. Physicians’ specialties were pri-
mary care (50), orthopedists (30) and rheumatologists (10). Each physician included 10 pa-
tients: 500 patients from primary care, 300 patients from orthopedists and 100 patients from 
rheumatologists providing data for a total of 900 patients. Physicians provided information 
from patient records on patient demographics and clinical characteristics including the ran-
dom sample as well as the over-sample.
As shown in Table I, which presents the demographic characteristics, individuals were 
predominantly female (63%) and the mean age was 66.6 years (SD 12.4). The mean body 
mass index (BMI) was 26.3 (SD 3.8), with 25% of patients being reported as obese (BMI>30) 
by physicians. There was a high presence (46.5%) of patients who were retired, and about one 
third (32.1%) were employed (25.9% in full time, 6.2% in part-time employment). Only 3% 
of patients reported being retired due to OA.
Among the study sample, 237 (26%) patients were classified by physicians as having mild 
OA, 482 (54%) moderate OA and 181 (20%) had severe OA (Table I). Among 900 patients, 
699 (129 %) patients reported additional conditions on top of their OA. The most frequently 
were cardiovascular conditions (66%), neurological conditions (33%) and diabetes/endocrine 
diseases 32% (Table I).
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As to the clinical profile 7% of patients 
were classified as rapidly deteriorating, 38% 
as slowly deteriorating, 45% were reported 
as having a stable disease and 10% as cur-
rently improving their disease status. Joints 
mostly affected by OA were the knee 
(40.9%) and the back (38.7%) followed by 
the hip (27.9%) and the shoulder (20.3%), 
with relatively lower frequencies for the 
hand, neck and wrist. Looking at patient’s 
functionality, as recorded by the treating 
physician, patients appeared to stand on the 
higher area of the spectrum, with 43% of pa-
tients being rated 6 or higher (on a scale 0-10 
where 0 implies full functionality and 10 
complete impairment) (Table I).
The average number of OA-related 
visits to the physician reported in the past 
3 months by patients was 3.75 and an ad-
ditional 1 visit was reported to a different 
health care professional (HCP) (on average, 
about 19/year). The average number of med-
ical and other HCP visits appeared higher 
in the elderly (age group 74-89), in patients 
with higher pain severity (NRS 7-10) and in 
severe patients (according to both patients’ 
and physicians’ assessed disease severity) 
(Supplementary Figure 1). Severe patients 
reported respectively 24.3 and 22.3 visits 
per year (severity assessed by patients and 
physicians, respectively).
Prescribed OA Treatment Patterns
Exposure to pain-related treatments 
among OA patients was assessed in relation 
to disease progression, disease severity and 
pain severity.
Duration of treatment was the lowest in 
patients deteriorating rapidly; in (both rap-
idly and slowly) deteriorating patients on 
average 2 classes of drugs were used. The 
highest rate of strong opioids (46%) and an-
algesics (38%) use was recorded in patients 
deteriorating rapidly. In stable and improv-
ing patients, strong opioids were used only 
by a minority of patients (7% and 5%, re-
spectively) (Figure 1).
No difference in duration of treatment 
by severity of disease was reported. Severe 
patients were prescribed 2 classes of drugs 
(vs 1 in mild and moderate patients); severe 
patients were more likely to be prescribed 
strong opioids (37%), weak opioids (26%) 
and analgesics (32%), whilst moderate pa-
tients used more NSAIDs (74%), but still 
one in five (20%) of moderate patients used 
weak opioids (Figure 2).
Duration of treatment by severity of pain (NRS 0-10), revealed no differences although 
there seemed to be a tendency towards a longer treatment duration with the decrease of pain 
severity. Severe pain patients (NRS 7-10) and moderate pain patients (NRS 4-6) used 2 class-
es of drugs (vs 1 in mild pain patients NRS 0-3); severe pain patients used more of all classes 
Characteristic Value
Mean age, years (n=900) 66.6
Gender, % M/F (n=889) 37/63
BMI (n=899) 26.3
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Table I. Demographics and clinical characteristics of patients with OA
Figure 1. Drug classes by disease progression
1 Non-opioid /non-NSAID
2 Other include: Corticosteroids, Opioid Combination, Viscosupplements, Glycosaminoglycans, Other Analgesic, Immunosuppressant, Monoclonal 
antibodies, Antidepressants, Anticonvulsant, Disease modifying antirheumatic drugs (DMARD), Bisphosphonate
Figure 2. Drug classes by disease severity
1 Non-opioid /non-NSAID
2 Other include: Corticosteroids, Opioid Combination, Viscosupplements, Glycosaminoglycans, Other Analgesic, Immunosuppressant, Monoclonal 
antibodies, Antidepressants, Anticonvulsant, Disease modifying antirheumatic drugs (DMARD), Bisphosphonate
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As to the clinical profile 7% of patients 
were classified as rapidly deteriorating, 38% 
as slowly deteriorating, 45% were reported 
as having a stable disease and 10% as cur-
rently improving their disease status. Joints 
mostly affected by OA were the knee 
(40.9%) and the back (38.7%) followed by 
the hip (27.9%) and the shoulder (20.3%), 
with relatively lower frequencies for the 
hand, neck and wrist. Looking at patient’s 
functionality, as recorded by the treating 
physician, patients appeared to stand on the 
higher area of the spectrum, with 43% of pa-
tients being rated 6 or higher (on a scale 0-10 
where 0 implies full functionality and 10 
complete impairment) (Table I).
The average number of OA-related 
visits to the physician reported in the past 
3 months by patients was 3.75 and an ad-
ditional 1 visit was reported to a different 
health care professional (HCP) (on average, 
about 19/year). The average number of med-
ical and other HCP visits appeared higher 
in the elderly (age group 74-89), in patients 
with higher pain severity (NRS 7-10) and in 
severe patients (according to both patients’ 
and physicians’ assessed disease severity) 
(Supplementary Figure 1). Severe patients 
reported respectively 24.3 and 22.3 visits 
per year (severity assessed by patients and 
physicians, respectively).
Prescribed OA Treatment Patterns
Exposure to pain-related treatments 
among OA patients was assessed in relation 
to disease progression, disease severity and 
pain severity.
Duration of treatment was the lowest in 
patients deteriorating rapidly; in (both rap-
idly and slowly) deteriorating patients on 
average 2 classes of drugs were used. The 
highest rate of strong opioids (46%) and an-
algesics (38%) use was recorded in patients 
deteriorating rapidly. In stable and improv-
ing patients, strong opioids were used only 
by a minority of patients (7% and 5%, re-
spectively) (Figure 1).
No difference in duration of treatment 
by severity of disease was reported. Severe 
patients were prescribed 2 classes of drugs 
(vs 1 in mild and moderate patients); severe 
patients were more likely to be prescribed 
strong opioids (37%), weak opioids (26%) 
and analgesics (32%), whilst moderate pa-
tients used more NSAIDs (74%), but still 
one in five (20%) of moderate patients used 
weak opioids (Figure 2).
Duration of treatment by severity of pain (NRS 0-10), revealed no differences although 
there seemed to be a tendency towards a longer treatment duration with the decrease of pain 
severity. Severe pain patients (NRS 7-10) and moderate pain patients (NRS 4-6) used 2 class-
es of drugs (vs 1 in mild pain patients NRS 0-3); severe pain patients used more of all classes 
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Table I. Demographics and clinical characteristics of patients with OA
Figure 1. Drug classes by disease progression
1 Non-opioid /non-NSAID
2 Other include: Corticosteroids, Opioid Combination, Viscosupplements, Glycosaminoglycans, Other Analgesic, Immunosuppressant, Monoclonal 
antibodies, Antidepressants, Anticonvulsant, Disease modifying antirheumatic drugs (DMARD), Bisphosphonate
Figure 2. Drug classes by disease severity
1 Non-opioid /non-NSAID
2 Other include: Corticosteroids, Opioid Combination, Viscosupplements, Glycosaminoglycans, Other Analgesic, Immunosuppressant, Monoclonal 
antibodies, Antidepressants, Anticonvulsant, Disease modifying antirheumatic drugs (DMARD), Bisphosphonate
except NSAIDs, which still represent the drug class mostly used in all groups, with consump-
tion being particularly higher in mild and moderate pain patients (Figure 3).
On average, across all patient subgroups about 44% of patients progressed to a second 
line, 19% to a third line and only 2% progressed to a fourth line of treatment, with a ten-
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dency to increase the number of classes and particularly to add weak and strong opioids. 
In patients whose disease was classified as mild only a minority progressed to second 
(26%), third (10%) and fourth (1%) line of treatment. Most used treatment classes in mild 
patients were NSAIDs and analgesics with a very limited number of cases in which both 
weak and strong opioids were used (in second and third line of treatment) (Supplemen-
tary Figure 2).
In moderate patients about 43% of subjects progressed to a second line, 17% to a third line 
and less than 1% progressed to a fourth line of treatment, with a tendency to added weak and 
strong opioids . 67% of patients classified as severe progress to second line, 31% of patients 
progressed to third and 7% to fourth line of treatment; percentage transitions across treatment 
lines in severe patients were the highest (so severe patients show to be treated with more drugs 
and more treatment lines than any other severity group). Also, in severe patients there was a 
wider use of strong opioids, especially in patients progressing to the third and fourth line of 
treatment. Of note, in severe patients the mean pain score was 7, irrespective of treatment line.
Physicians reported their satisfaction with treatment in relation to 651 patients for which 
a full treatment regimen was recorded (Supplementary Figure 3). In 26.6% of cases (n=173) 
they reported being dissatisfied (this includes Neither satisfied nor dissatisfied; Somewhat 
dissatisfied; Very dissatisfied). Among these 173 cases, reasons for dissatisfaction were in-
vestigated, with physicians reporting that in 37% of cases they find inadequate response and 
in 27% lack of improvement in patient quality of life; another 12% of dissatisfaction reports 
can be attributed to side effects (notably local reactions to injections; severity of side effects 
suffered; number of side effects suffered).
Patients reported their satisfaction with OA treatment(s) (Supplementary Figure 4). In 
51% of cases (n=114) they reported being dissatisfied (this includes Neither satisfied nor 
dissatisfied; Somewhat dissatisfied; Very dissatisfied). Dissatisfaction with treatment seems 
more marked in the elderly (≥74 years old) (64%), obese patients (65%), and in severe pa-
tients as assessed by both patients (81%) and physicians (69%).
Patients reported on OA-related surgeries (Supplementary Figure 5). The average inci-
dence of surgery was 14% in all patients (n=242), with higher percentages reported by pa-
tients in the oldest age group (24%), by obese (BMI>30) vs non obese patients (32% vs 10%), 
by patients reporting severe pain (25%), and by patients classified as severe according to both 
patient’s (31%) and physician’s (26%) disease severity assessment. 
Figure 3. Drug classes by pain severity
1 Non-opioid /non-NSAID
2 Other include: Corticosteroids, Opioid Combination, Viscosupplements, Glycosaminoglycans, Other Analgesic, Immunosuppressant, Monoclonal 
antibodies, Antidepressants, Anticonvulsant, Disease modifying antirheumatic drugs (DMARD), Bisphosphonate
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Physical Functioning
Physical functioning was reported by patients using pain, physical function and stiffness 
scores from the WOMAC, each on a scale 0-10 (Figure 4). In the total population, patients 
classified as severe, according to physician’s and patient’s disease severity assessment, re-
ported WOMAC score 19.8 and 18.9, respectively. In addition, a higher WOMAC score was 
reported in elderly (age 74-89) and obese (BMI>30) patients, 16.1 and 15.9, respectively.
Mobility limitation, need for a walking aid, need for help with daily activities, and suffering a 
fall were assessed by patient responses to stand-alone questions related to functional limitations.
Among 239 patients, 141 (59%) reported that OA had an impact on physical mobility 
which seems to affect mostly patients in older age cohorts (63-73 and 74-89) with impair-
ment reported by 67% and 83% of patients, respectively. Higher rate of mobility limitation 
was noted in obese patients (71%) and, in patients with moderate and severe disease severity, 
according to patients’ severity assessment (66% and 88% respectively) as well as according 
to physicians’ severity assessment (66% and 83% respectively) (Supplementary Figure 6).
Patients reported their need help for getting around (Supplementary Figure 7). On aver-
age, 29% reported they need a cane/walking stick, 3% they need a walking frame, 1% re-
ported they need a wheelchair. Higher percentages were recorded by patients in the older age 
class; male patients (42% of them need cane/walking stick), obese patients (in total 59% of 
them need some sort of support) and severe patients according to patients’ disease severity 
assessment (48% need support) as well as according to physicians’ severity assessment (52% 
need support).
22% of 237 patients (about one in five individuals) reported that OA generates the need for 
some help with daily activities or tasks (Supplementary Figure 8). This seems to affect mostly 
the elderly (74-89) with external need reported by 48% of patients, obese patients (BMI>30) 
with 36%, patients with longer disease duration with reported 24%, and severe patients ac-
cording to patients’ disease severity assessment (47%) as well as according to physicians’ 
severity assessment (46%).
Patients reported on falls attributed to OA. As shown the average incidence of falls was 
21% in all patients (n=244) with higher percentages reported by patients in the oldest age 
group (21%), by women vs men (23% vs 17%), by obese (BMI>30) vs non obese patients 
(28% vs 19%), by patients reporting severe pain (49%), and by patients classified as severe 
according to both patient’s (40%) and physician’s (32%) disease severity assessment (Supple-
mentary Figure 9).
A total of 62 patients reported on the number of hours per week that family, friends or 
professional caregivers provided to help care (Supplementary Figure 10). Patients were as-
Figure 4. WOMAC scores
BMI = Body mass of index; DD = Disease duration; DS* = Disease Severity assessed by patient; DS** = Disease severity assessed by physician; 
PF = Physical functioning; PS = Pain Severity
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sisted for about 13.6 hours/week on average. Patient groups that required more assistance 
were those in the 65-73 age category (17.9 hrs/wk), obese patients (30.3 hrs/wk), patients with 
higher pain score (20.6 hrs/wk) and patients classified as severe according to both patient’s 
(21.7 hrs/wk) and physician’s (17.0 hrs/wk) disease severity assessment.
HRQoL
HRQoL, assessed by the EQ-5D-5L VAS recorded the patient’s self-rated health on a ver-
tical visual analogue scale, where the endpoints are labelled ‘The best health you can imagine’ 
and ‘The worst health you can imagine’ (Figure 5). Patients scored their health at an average 
of 62.5 with lower scores being recorded for the elderly (52.2), patients with the highest pain 
severity (53.5) and for patients being classified as severe, according to both physicians (47.8) 
and patients (51.1) disease severity assessment.
Work Productivity and Daily Activity
WPAI score on the overall work productivity was collected on 237 subjects (Figure 6). On 
average OA patients reported their work productivity was impaired by 45% due to OA prob-
lems. Higher WPAI scores were reported by the oldest patients’ age group (58%), by obese 
patients (57%), by patients reporting more severe pain (66%) and by patients classified as 
severe according to both patient’s (71%) and physician’s (67%) disease severity assessment.
Patients reported the effect of OA on their work productivity over the past 7 days, on a 
scale 0-10 (0=no effect; 10=completely preventing work) (Supplementary Figure 11). Mean 
score across all patients was 2.5; higher effect was reported by patients aged 65-73 years (5.0), 
female (2.9), obese patients (3.3) patients with duration of disease>1 year (3.2), patients with 
highest pain severity score (4.5) and patients classified as severe by both patient’s and physi-
cian’s assessment (score 5.4 and 4.5, respectively).
73 patients reported having missed on average 3.5 hours of work over the past 7 days, with 
the highest work loss recorded by patients aged 65-73 years (14 hours), male (6.4 hours), pa-
tients with highest pain severity score (12.9) and patients classified as severe by both patient’s 
and physician’s assessment (16.8 and 27 hours, respectively) (Supplementary Figure 12).
Almost all patients (n=237) reported on the effect of OA on their ability to perform daily 
activities over the past 7 days, on a scale 0-10 (0=no effect; 10=completely preventing activ-
ity) (Supplementary Figure 13). Mean score across all patients was 4.5; higher effect was 
reported by patients aged 74-89 years (5.8), obese patients (5.7), patients with highest pain 
severity score (6.6) and patients classified as severe by both patient’s and physician’s assess-
ment (score 7.1 and 6.7, respectively).
Figure 5. EQ5D VAS score
BMI = Body mass of index; DD = Disease duration; DS* = Disease Severity assessed by patient; DS** = Disease severity assessed by physician; 
PF = Physical functioning; PS = Pain Severity
Figure 6. WPAI score
BMI = Body mass of index; DD = Disease duration; DS* = Disease Severity assessed by patient; DS** = Disease severity assessed by physician; 
PF = Physical functioning; PS = Pain Severity
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sisted for about 13.6 hours/week on average. Patient groups that required more assistance 
were those in the 65-73 age category (17.9 hrs/wk), obese patients (30.3 hrs/wk), patients with 
higher pain score (20.6 hrs/wk) and patients classified as severe according to both patient’s 
(21.7 hrs/wk) and physician’s (17.0 hrs/wk) disease severity assessment.
HRQoL
HRQoL, assessed by the EQ-5D-5L VAS recorded the patient’s self-rated health on a ver-
tical visual analogue scale, where the endpoints are labelled ‘The best health you can imagine’ 
and ‘The worst health you can imagine’ (Figure 5). Patients scored their health at an average 
of 62.5 with lower scores being recorded for the elderly (52.2), patients with the highest pain 
severity (53.5) and for patients being classified as severe, according to both physicians (47.8) 
and patients (51.1) disease severity assessment.
Work Productivity and Daily Activity
WPAI score on the overall work productivity was collected on 237 subjects (Figure 6). On 
average OA patients reported their work productivity was impaired by 45% due to OA prob-
lems. Higher WPAI scores were reported by the oldest patients’ age group (58%), by obese 
patients (57%), by patients reporting more severe pain (66%) and by patients classified as 
severe according to both patient’s (71%) and physician’s (67%) disease severity assessment.
Patients reported the effect of OA on their work productivity over the past 7 days, on a 
scale 0-10 (0=no effect; 10=completely preventing work) (Supplementary Figure 11). Mean 
score across all patients was 2.5; higher effect was reported by patients aged 65-73 years (5.0), 
female (2.9), obese patients (3.3) patients with duration of disease>1 year (3.2), patients with 
highest pain severity score (4.5) and patients classified as severe by both patient’s and physi-
cian’s assessment (score 5.4 and 4.5, respectively).
73 patients reported having missed on average 3.5 hours of work over the past 7 days, with 
the highest work loss recorded by patients aged 65-73 years (14 hours), male (6.4 hours), pa-
tients with highest pain severity score (12.9) and patients classified as severe by both patient’s 
and physician’s assessment (16.8 and 27 hours, respectively) (Supplementary Figure 12).
Almost all patients (n=237) reported on the effect of OA on their ability to perform daily 
activities over the past 7 days, on a scale 0-10 (0=no effect; 10=completely preventing activ-
ity) (Supplementary Figure 13). Mean score across all patients was 4.5; higher effect was 
reported by patients aged 74-89 years (5.8), obese patients (5.7), patients with highest pain 
severity score (6.6) and patients classified as severe by both patient’s and physician’s assess-
ment (score 7.1 and 6.7, respectively).
Figure 5. EQ5D VAS score
BMI = Body mass of index; DD = Disease duration; DS* = Disease Severity assessed by patient; DS** = Disease severity assessed by physician; 
PF = Physical functioning; PS = Pain Severity
Figure 6. WPAI score
BMI = Body mass of index; DD = Disease duration; DS* = Disease Severity assessed by patient; DS** = Disease severity assessed by physician; 
PF = Physical functioning; PS = Pain Severity
DISCUSSION
In this cross-sectional study, Italian patients with severe OA disease severity reported 
significant burdens that affected multiple aspects of their lives, encompassing reductions in 
physical functioning, greater treatment needs, reduced HRQoL, and impairments in work 
productivity and daily activities.
The high prevalence of OA among the elderly is well known [23-25]. Age-related changes 
occurring in tissues besides articular cartilage may contribute to the development of OA and 
are much more intense in the presence of obesity [26]. In the current study, burdens affecting 
OA patients were higher among the elderly and obese individuals.
OA is associated with a significant functional impairment that can result in disability [27]. 
The results of this study demonstrated that at each level of OA severity, the corresponding 
magnitude of functional impairment was different, with the greatest impact reported by physi-
cians and patients who rated OA as severe. Patients with severe OA disease were more likely 
than mild and moderate-patients to report impairment in physical function, pain, stiffness, 
specific needs such as for a walking aid or help with daily activities, help care and that they 
suffered a fall. These results are in line with several cross-sectional studies that found a rela-
tionship between disease severity and physical function [28-31].
In OA patients, HRQoL is negatively affected [32, 33]. In this study, HRQoL, as measured 
by the EQ-5D VAS was lower among patients classified as severe, according to both physi-
cian’s and patient’s disease severity assessment. HRQoL was also lower among patients with 
higher pain severity. A systemic review by Vitaloni et al. revealed a substantial impact on 
quality of life (QoL) in patients affected by knee osteoarthritis (KOA). All reviewed studies 
reported worse QoL in KOA patients when compared to a control group. When females were 
compared to males, females reported worse QoL. Obesity, as well as lower level of physical 
activity, were also reported with lower QoL scores [34].
Previous studies have demonstrated an association between OA and reduced work pro-
ductivity and the ability to perform daily activities [35, 36] and such impairments were also 
reported by patients in this study. These impairments, as measured by the WPAI score, were as-
sociated with higher disease severity and pain levels. Work productivity and daily activity im-
pairments were higher in patients with highest pain severity score and in patients classified as 
severe by both patient’s and physician’s assessment. This finding is consistent with the results 
of other studies in OA showing that pain and disease severity has a negative association with 
employment status and productivity, including both absenteeism and presenteeism [30,31].
The current study revealed a higher medication burden among patients with OA, and a 
greater proportion of these patients who were prescribed potent drugs. Even if NSAIDs are 
10 Farmeconomia. Health economics and therapeutic pathways 2021; 22(1)
Osteoarthritis in Italy: Impact on Health-Related Quality of Life and Health Care Resources
considered first-line treatment for OA, opioids were the most frequently prescribed medication 
class in this Italian patients’ population. There was a higher prescribing rate of strong and weak 
opioids in patients with severe pain as well as in patients whose OA was classified as severe 
by both patient’s and physician’s assessment. This high rate of opioid prescribing is in accord 
with other studies that have shown opioids to be the most frequently prescribed pain-related 
medications in patients with OA [37]. In particular patients with severe disease reported use 
of two treatment regimens for OA. Additionally, physicians reported treatment dissatisfaction 
related to inadequate response and lack of improvement in patient quality of life while dissat-
isfaction from patients seems more marked in the elderly, obese patients, and severe patients.
Across all classes of prescription medications, approximately only one third of OA pa-
tients reported being very or extremely satisfied with their current medication, presenting 
some relevant problems, such as poor compliance / adherence to the treatments. Kingsbury et 
al. showed that 42% of Italian OA patients considered themselves to be fully adherent to their 
medication [36] and, the most common classes of prescription medication were NSAIDs and 
COX-2 inhibitors [36,38].
Healthcare resource utilization relative to individuals with OA is responsible for a substan-
tial proportion of the economic burden of OA. These resources include not only pharmacologic 
and other therapies related for OA, but also management of treatment-related complications 
and surgery/ rehabilitation [18,39-42]. In the current study, OA patients classified as severe 
reported higher percentages of OA-related surgeries. In Italy during 2015 were performed 
around 181.738 surgeries (56.3% relates to the hip, 38.6% knee, 3.9%, 0.3% and 0.9% respec-
tively shoulder, ankle and other joints). Since 2001 to 2015, the average annual increase in the 
number of total interventions was 4.1% [43]. The incremental healthcare costs of people with 
osteoarthritis compared to those without the disease reaches a maximum when osteoarthritis-
related surgery becomes necessary [15]. The main direct health-related cost driver is the total 
joint arthroplasty [44]. The socioeconomic burden of total joint arthroplasties generated ad-
ditional costs due to relapses, need for intervention review, adverse events (e.g. infections, 
thrombosis, and pulmonary embolisms) and subsequently to the rehabilitation process, in hos-
pital and at home [45]. The steady increase, year after year, of surgery incidence led costs to 
grow [45-47] and this is expected also for the next future, in an ageing population [46].
As in previous studies that reported high rates of healthcare utilization among OA patients 
in terms of number of visits to a health care provider and hospitalizations [18,29,38,48], in 
the current study patients with OA utilized outpatient resources including medical and other 
health care professional (HCP) visits. This resource utilization was higher in patients with 
higher pain severity and in patients classified as severe by both patient’s and physician’s as-
sessment. In Italy hospitalization represented 40% of the medical costs and among different 
admissions, those in rehabilitative care were the most expensive due to a stay in hospital 
prolonged up to 50 days in patients operated for arthroprothesis [18].
Interpretation and extrapolation of these results are subject to study limitations. These 
limitations include study participation based on agreement by physicians and patients. It is 
therefore possible that individuals who participated may have characteristics and perceptions 
different from those who refused to participate, thereby introducing selection bias and reduc-
ing generalizability. In addition, we are unable to attribute linked causality between OA and 
reported outcomes, since it is possible that co-morbid conditions and other factors may have 
contributed in part to the differences described. Furthermore, statistical comparisons were not 
conducted between the patient groups limiting the analysis of relevant differences. 
CONCLUSION
This real-world-cross-sectional study demonstrated an increase in the scoring for all dimen-
sions of QoL as well as in the use of resources as OA disease severity worsened. The burdens were 
higher among severe patients versus moderate and mild patients. Novel therapeutic agents that 
improve OA symptom management may lead to significant healthcare resource utilization savings.
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Figure 1. Average number of OA-related medical visits in the past 3 months
BMI = Body mass of index; DD = Disease duration; DS* = Disease Severity assessed by patient; DS** = Disease Severity assessed by physician; 
HCP = Health Care Professional; PS = Pain Severity
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Figure 2. Treatment history by disease severity
1 (non-opioid /non-NSAID)
2 Other include: Corticosteroids, Opioid Combination, Viscosupplements, Glycosaminoglycans, Other Analgesic, Immunosuppressant, Monoclonal 
antibodies, Antidepressants, Anticonvulsant, Disease modifying antirheumatic drugs (Dmard), Bisphosphonate
Figure 3. 3A Physician’s satisfaction with treatment (n=651); 3B Reason for dissatisfaction (n=173)
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Figure 4. Patient’s satisfaction with treatment
BMI = Body mass of index; DD = Disease duration; DS* = Disease Severity assessed by patient; DS** = Disease Severity assessed by physician
Figure 5. Surgeries due to OA
BMI = Body mass of index; DD = Disease duration; DS* = Disease Severity assessed by patient; DS** = Disease Severity assessed by physician; 
PS = Pain Severity
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Figure 6. Impact on physical mobility
BMI = Body mass of index; DD = Disease duration; DS* = Disease Severity assessed by patient; DS** = Disease Severity assessed by physician
Figure 7. Use of walking aids
BMI = Body mass of index; DD = Disease duration; DS* = Disease Severity assessed by patient; DS** = Disease Severity assessed by physician
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Figure 8. Need for help in daily activity
BMI = Body mass of index; DD = Disease duration; DS* = Disease Severity assessed by patient; DS** = Disease Severity assessed by physician
Figure 9. Falls
BMI = Body mass of index; DD = disease duration; DS* = Disease Severity assessed by patient; DS** = Disease Severity assessed by physician; 
PS = Pain Severity
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Figure 10. Hours family and professional caregiver
BMI = Body mass of index; DD = disease duration; DS* = Disease Severity assessed by patient; DS** = Disease Severity assessed by physician; 
PS = Pain Severity
Figure 11. Work productivity
BMI = Body mass of index; DD = disease duration; DS* = Disease Severity assessed by patient; DS** = Disease Severity assessed by physician; 
PS = Pain Severity
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Figure 12. Hours missed from work
BMI = Body mass of index; DD = disease duration; DS* = Disease Severity assessed by patient; DS** = Disease Severity assessed by physician; 
PS = Pain Severity
Figure 13. Ability to perform daily activities
BMI = Body mass of index; DD = disease duration; DS* = Disease Severity assessed by patient; DS** = Disease Severity assessed by physician; 
PS = Pain Severity
All (n=237)
